skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: PRODUCTION OF RADIOACTIVE IODINE.

Conference ·
OSTI ID:787626

Probably the most widely used cyclotron produced radiohalogen is I-123. It has gradually replaced I-131 as the isotope of choice for diagnostic radiopharmaceuticals containing radioiodine. It gives a much lower radiation dose to the patient and the gamma ray energy of 159 keV is ideally suited for use in a gamma camera. The gamma ray will penetrate tissue very effectively without excessive radiation dose. For this reason, it has in many instances replaced the reactor produced iodine-131 (Lambrecht and Wolf 1973). A great number of radiopharmaceuticals have been labeled using I-123 and the number is increasing. One of the most promising uses of I-123 is in the imaging of monoclonal antibodies to localize and visualize tumors. However, preclinical and clinical experiences with radiolabeled antibodies have not realized the expectations regarding specificity and sensitivity of tumor localization with these agents. It appears that much of the administered activity is not associated with the tumor site and only a small fraction actually accumulates there. Work continues in this area and tumor-associated antigens can be targets for specific antibody reagents.

Research Organization:
Brookhaven National Lab. (BNL), Upton, NY (United States)
Sponsoring Organization:
USDOE Office of Energy Research (ER) (US)
DOE Contract Number:
AC02-98CH10886
OSTI ID:
787626
Report Number(s):
BNL-68599; KP140102; R&D Project: CO11; KP140102; TRN: US0109338
Resource Relation:
Conference: TECHNICAL MEETING OF PROJECT COUNTERPARTS ON CYCLOTRON PRODUCTION OF IODINE 123, INSTITUTE OF NUCLEAR AND ENERGY RESEARCH, SAO PAULO (BR), 08/08/2001--08/10/2001; Other Information: PBD: 8 Aug 2001
Country of Publication:
United States
Language:
English